Kobiolabs Co., South Korea's new drug development company for microbiomes, announced on Tuesday that it has signed a memorandum of understanding for comprehensive business cooperation with Kakao Healthcare.
The agreement aims to explore personalized precision medical and nutrition solutions related to microbiome technology, as well as the launch of a digital bio-healthcare platform.
The microbiome is a term coined from microbiota and genome, referring to microbiota and symbiotic microorganisms in the human body. The field has recently gained attention in pharmaceuticals and health-functional foods.
Combining its own data with Kakao Healthcare's digital platform technology, Kobiolabs expects to provide sophisticated services. The partnership is expected to enhance the development of microbiome-related products and services, furthering advancements in the field of personalized medicine.
Write to Yena Kim at
yena@hankyung.com
